Nicolas Boutard

Nicolas Boutard

Auto-generated profile, based on publicly available information

Nicolas Boutard

Selvita S.A. (now Ryvu Therapeutics), Park Life Science, ul. Bobrzynskiego 14, 30-348, Kraków, Poland

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2012 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
AJAndrew Jamieson
Andrew Jamieson
NBNicolas Boutard
Nicolas Boutard
DSDavid Sabatino
David Sabatino
William D. LubellWilliam D. Lubell
William D. Lubell

19 May 2009 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
AJAndrew Jamieson
Andrew Jamieson
NBNicolas Boutard
Nicolas Boutard
KBKim Beauregard
Kim Beauregard
MBMandar S. Bodas
Mandar S. Bodas
Huy OngHuy Ong
Huy Ong
William D. LubellWilliam D. Lubell
William D. Lubell

4 June 2009 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
GFGil Fridkin
Gil Fridkin
NBNicolas Boutard
Nicolas Boutard
William D. LubellWilliam D. Lubell
William D. Lubell

1 September 2017 in ACS Chemical Biology
Verified
Journal Article
Open access
FFFederico Falchi
Federico Falchi
EGElisa Giacomini
Elisa Giacomini
TMTiziana Masini
Tiziana Masini
NBNicolas Boutard
Nicolas Boutard
LILorenza Di Ianni
Lorenza Di Ianni
ACAndrea Cavalli
Andrea Cavalli
In BRCA2-defective cells, poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors can trigger synthetic lethality, as two independent DNA-repairing mechanisms are simultaneously impaired. Here, we have pharmacologically induced synthetic lethality, which was triggered by combining two different small organic molecules. When administered with a BRCA2–Rad51 disruptor in nonmutant cells, Olaparib showed anticancer activity comparable to that shown when administered alone in BRCA2-defective cells. This strategy could represent an innovative approach to anticancer drug discovery and could be extended to other synthetic lethality pathways.

1 December 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DHDavid Harrison
David Harrison
NBNicolas Boutard
Nicolas Boutard
KBKrzysztof Brzozka
Krzysztof Brzozka
MBMarta Bugaj
Marta Bugaj
SCStefan Chmielewski
Stefan Chmielewski
AWAlan P. Watt
Alan P. Watt

30 November 2009 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
NBNicolas Boutard
Nicolas Boutard
AJAndrew Jamieson
Andrew Jamieson
HOHuy Ong
Huy Ong
William D. LubellWilliam D. Lubell
William D. Lubell